Emergent Q3 revenue $231.1M beats guidance; raises FY2025 revenue & EBITDA view

Emergent BioSolutions Inc.

2025-Q3 EPS reported $1.89 revenue$594,200,000

Total revenue $231.1M (above Q3 guidance high by $21M); net income $51.2M ($0.91 EPS).
Adjusted EBITDA $87.8M (38% margin); adjusted EPS $1.06; gross margin expanded 300bps to 54%.
Naloxone segment down 21% to $74.9M; MCM down 18% to $142.5M; Other Products up 91% to $57.5M.
FY2025 guidance raised: revenue $775-$835M (from $765-$835M), adjusted EBITDA $195-$210M (from $175-$200M).
Secured $56M ACAM2000, $52M CNJ-016, $30M CYFENDUS, $29M international MCM contracts in Q3.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.